Ranbaxy, Samsung, Zillow, Scotch: Intellectual Property

A gap in U.S. patent law has kept cheap copies of Novartis AG’s heart drug Diovan off the market for 18 months, costing U.S. consumers and insurers as much as $900 million in potential savings.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.